197 related articles for article (PubMed ID: 9450795)
1. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
Storring PL; Tiplady RJ; Gaines Das RE; Stenning BE; Lamikanra A; Rafferty B; Lee J
Br J Haematol; 1998 Jan; 100(1):79-89. PubMed ID: 9450795
[TBL] [Abstract][Full Text] [Related]
2. Lectin-binding assays for the isoforms of human erythropoietin: comparison of urinary and four recombinant erythropoietins.
Storring PL; Tiplady RJ; Gaines Das RE; Rafferty B; Mistry YG
J Endocrinol; 1996 Sep; 150(3):401-12. PubMed ID: 8882159
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®.
Capdeville P; Martin L; Cholet S; Damont A; Audran M; Ericsson M; Fenaille F; Marchand A
J Pharm Biomed Anal; 2021 Feb; 194():113750. PubMed ID: 33234415
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts.
Jelkmann W
Curr Med Chem; 2009; 16(10):1236-47. PubMed ID: 19355882
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo).
Llop E; Gutiérrez-Gallego R; Segura J; Mallorquí J; Pascual JA
Anal Biochem; 2008 Dec; 383(2):243-54. PubMed ID: 18804089
[TBL] [Abstract][Full Text] [Related]
6. Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation.
Yin B; Gao Y; Chung CY; Yang S; Blake E; Stuczynski MC; Tang J; Kildegaard HF; Andersen MR; Zhang H; Betenbaugh MJ
Biotechnol Bioeng; 2015 Nov; 112(11):2343-51. PubMed ID: 26154505
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.
Halstenson CE; Macres M; Katz SA; Schnieders JR; Watanabe M; Sobota JT; Abraham PA
Clin Pharmacol Ther; 1991 Dec; 50(6):702-12. PubMed ID: 1752115
[TBL] [Abstract][Full Text] [Related]
8. Effects of epoetin alfa on the central nervous system.
Cerami A; Brines ML; Ghezzi P; Cerami CJ
Semin Oncol; 2001 Apr; 28(2 Suppl 8):66-70. PubMed ID: 11395856
[TBL] [Abstract][Full Text] [Related]
9. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
Okano M; Sato M; Kaneko E; Kageyama S
Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
[TBL] [Abstract][Full Text] [Related]
10. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.
Park SS; Park J; Ko J; Chen L; Meriage D; Crouse-Zeineddini J; Wong W; Kerwin BA
J Pharm Sci; 2009 May; 98(5):1688-99. PubMed ID: 18781649
[TBL] [Abstract][Full Text] [Related]
11. Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.
Aachmann-Andersen NJ; Just Christensen S; Lisbjerg K; Oturai P; Meinild-Lundby AK; Holstein-Rathlou NH; Lundby C; Vidiendal Olsen N
PLoS One; 2014; 9(10):e110903. PubMed ID: 25335123
[TBL] [Abstract][Full Text] [Related]
12. The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins.
Storring PL; Gaines Das RE
J Endocrinol; 1992 Sep; 134(3):459-84. PubMed ID: 1402553
[TBL] [Abstract][Full Text] [Related]
13. Detection of recombinant human erythropoietin in urine by isoelectric focusing.
Breidbach A; Catlin DH; Green GA; Tregub I; Truong H; Gorzek J
Clin Chem; 2003 Jun; 49(6 Pt 1):901-7. PubMed ID: 12765986
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
15. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.
Corbo DC; Suddith RL; Sharma B; Naso RB
Am J Hosp Pharm; 1992 Jun; 49(6):1455-8. PubMed ID: 1529989
[TBL] [Abstract][Full Text] [Related]
16. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
[TBL] [Abstract][Full Text] [Related]
17. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
Veys N; Dhondt A; Lameire N
Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
[TBL] [Abstract][Full Text] [Related]
18. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
19. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells.
Nimtz M; Martin W; Wray V; Klöppel KD; Augustin J; Conradt HS
Eur J Biochem; 1993 Apr; 213(1):39-56. PubMed ID: 8477709
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective properties of epoetin alfa.
Cerami A; Brines M; Ghezzi P; Cerami C; Itri LM
Nephrol Dial Transplant; 2002; 17 Suppl 1():8-12. PubMed ID: 11812906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
